About Animab
Animab is a company based in Ghent (Belgium) founded in 2020. Animab has raised $13.97 million across 3 funding rounds from investors including VLAIO, Qbic Venture Partners and Seventure Partners. The company has 3 employees as of December 31, 2021. Animab offers products and services including Oral Antibodies and Antibody-Based Approach. Animab operates in a competitive market with competitors including Zoetis, Ceva, Bio-Sourcing, Phage Lab and Proteon Pharmaceuticals, among others.
- Headquarter Ghent, Belgium
- Employees 3 as on 31 Dec, 2021
-
Sectors
HealthcareAgriculture
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Animab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$13.97 M (USD)
in 3 rounds
-
Latest Funding Round
$9.95 M (USD), Series A
Nov 07, 2022
-
Investors
VLAIO
& 4 more
-
Employee Count
3
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Animab
Animab offers a comprehensive portfolio of products and services, including Oral Antibodies and Antibody-Based Approach.
Antibodies that target intestinal pathogens to improve livestock gut health.
Technology for preventing bacterial colonization in animal feed.
Funding Insights of Animab
Animab has successfully raised a total of $13.97M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $9.95 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Animab
Animab has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include VLAIO, Qbic Venture Partners and Seventure Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund investing in technological breakthroughs from universities.
|
Locked | Locked | Locked | |
|
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
|
Locked | Locked | Locked | |
|
Investments are made in sustainable agriculture and agribusiness.
|
Locked | Locked | Locked |
Investor details for Animab
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Animab
Investment portfolio details for Animab
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Animab
Detailed financials for Animab
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Animab Comparisons
Peer comparison for Animab
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Animab
Animab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zoetis, Ceva, Bio-Sourcing, Phage Lab and Proteon Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Animal medicines, vaccines, and diagnostics are manufactured and supplied.
|
|
| Locked | Locked | Locked |
Animal health therapeutics are developed and supplied globally by Ceva.
|
|
| Locked | Locked | Locked |
Biopharmaceuticals for animals are manufactured and supplied through partnerships.
|
|
| Locked | Locked | Locked |
Bacteriophage treatments for animal infections are developed by the company.
|
|
| Locked | Locked | Locked |
Therapeutics for animal infectious diseases are developed via phage platforms.
|
Detailed competitors of Animab
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Animab
Complete news archive for Animab
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Animab
Animab was founded in 2020.
Animab is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.
Alain Wille is the current CEO of Animab.
Animab is a funded company, having raised a total of $13.97M across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Animab is 3.
Animab was founded in 2020 in Ghent, Belgium, within the veterinary biotechnology sector. A proprietary monoclonal antibody platform is developed for treating intestinal infections in pigs. Oral antibiotics are offered as the flagship product to support piglet health during the post-weaning stage. The antibodies are designed to mimic IgA, enabling passage through colostrum and milk for protection of nursing animals. Operations focus on innovative solutions for animal health challenges.
Animab's top competitors include Zoetis, Ceva and Bio-Sourcing.
Animab offers Oral Antibodies and Antibody-Based Approach.
Animab has 5 investors. Key investors include VLAIO, Qbic Venture Partners, Seventure Partners, Agri Investment Fund, and V-Bio Ventures.